Why the study?
Does mild hepatic impairment affect the pharmacokinetics, pharmacodynamics, and safety of a single oral 90-mg dose of ticagrelor compared to normal liver function?
Does mild hepatic impairment affect the pharmacokinetics, pharmacodynamics, and safety of a single oral 90-mg dose of ticagrelor compared to normal liver function?
Mild hepatic impairment modestly increases ticagrelor exposure but does not affect pharmacodynamics or tolerability, indicating no dosage adjustment is necessary for these patients.
No takes yet. Share an insight, caveat, or question.
Supports no dose adjustment in mild hepatic impairment; extends PK/PD data but leaves open confirmation in larger cohorts.
Butler et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: